Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses (UKHVCSpoke003)
A Phase I Clinical Trial Investigating Immunisation Strategies Using DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses
UKHVC Spoke 003 is a randomised Phase I, two centre study which will explore the impact of shortening a vaccination regimen using deoxyribonucleic acid (DNA) (CN54ENV and ZM96GPN), Modified Vaccinia Ankara - C (MVA-C) and CN54rgp140 adjuvanted with glucopyranosyl lipid A adjuvant - aqueous form (GLA-AF). The study population will be 40 healthy male and female volunteers 18 to 45 years old who are at low risk of HIV infection are to be recruited.
Study participants will be immunised with trial immunogens:
- 8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
- 1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade-C 97CN54
- 100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
- 5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
All immunisations will be administered by the intramuscular route (IM). CN54gp140 and GLA will be mixed together before administration, and immunogens will be delivered in combination regimens
研究概览
详细说明
This is a phase I study exploring the safety and potency of five HIV vaccines in healthy volunteers. The main aim is to see whether three of the five vaccines can be given together rather than one after the other, in five rather than seven sets of vaccinations and a course shortened by eight weeks. All volunteers will receive three injections of the first two vaccines (DNA plasmids) and half will be randomly assigned to receive two injections each of the second (MVA-C) and subsequent vaccines (CN54rgp140 mixed with GLA-AF) during the same visit or two injections of the MVA-C followed by two of CN54rgp140 mixed with GLA-AF.
The investigators are interested in ensuring that the vaccines are safe and also that the immune responses in the two groups of volunteers are similar. The three vaccines have all been shown to stimulate the immune response to specific parts of the HIV virus and none are infectious. The first vaccine consists of two DNA plasmids. When injected into muscle cells small parts of the HIV virus which are encoded by the DNA are produced and these are then recognised by the immune system. The second vaccine MVAC, is derived from vaccinia virus which has been modified so that it cannot divide. The virus (Modified Vaccinia Ankara (MVA)) actually expresses the same portions of HIV as the DNA and results in amplification of the responses seen. The third vaccine is a synthetically produced component of the HIV viral outer coat and it will be administered with an additive which has been shown to greatly enhance particular types of immune response which have recently been shown to play a role in protection against infection
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Greater London、英国、W2 1PG
- Imperial College London
-
-
Surrey
-
Guildford、Surrey、英国、GU2 7XP
- Surrey Clinical Research Centre, University of Surrey
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Man or woman aged between 18 and 45 years on the day of screening
- Available for follow-up for the duration of the study (up to ~10 months from enrolment)
At low risk of HIV and willing to remain so for the duration of the study defined as:
- no history of injecting drug use in the previous ten years
- no gonorrhoea or syphilis in the last six months
- no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months
- no unprotected anal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative
- no unprotected vaginal intercourse in the last six months outside a relationship with a regular known/presumed HIV negative partner
- Willing to undergo an HIV test
- Willing to undergo a genital infection screen if indicated by sexual history
- If heterosexually active female, using an effective method of contraception with partner other than an IUCD/IUS (combined oral contraceptive pill; injectable or implanted contraceptive; consistent record with condoms if using these; physiological or anatomical sterility in self or partner) from 14 days prior to the first vaccination until 4 months after the last, and willing to undergo urine pregnancy tests prior to each vaccination
- If heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination
- Agree to abstain from donating blood for three months after the end of their participation in the trial, or longer if necessary
- Registered with a general practitioner (GP) for at least the past three months
- Satisfactory response received from GP before randomisation
- Willing and able to give written informed consent
Exclusion Criteria:
- Pregnant or lactating
- Presence of an IUCD (intrauterine contraceptive device)/IUS (intrauterine system)
Clinically relevant abnormality on history or examination including
- history of grand-mal epilepsy, seizure disorder or any history of prior seizure
- severe eczema
- liver disease with inadequate hepatic function
- any skin condition which may interfere with the trial assessment on the injection site
- haematological, metabolic, gastrointestinal or cardio-pulmonary disorders
- uncontrolled infection; toxic shock syndrome; autoimmune disease, immunodeficiency or use of immunosuppressives in preceding 3 months
- Known hypersensitivity to any component of the vaccine formulations used in this trial, or have severe or multiple allergies to drugs or pharmaceutical agents
History of severe local or general reaction to vaccination defined as
- local: extensive, indurated redness and swelling involving the major circumference of the arm, not resolving within 72 hours
- general: fever >= 39.5°C within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
- Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of enrolment
- Receipt of an experimental vaccine containing HIV antigens at any time in the past
- Receipt of blood products or immunoglobin within 4 months of screening
- Participation in another trial of a medicinal product, completed less than 30 days prior to enrolment
- HIV 1 or 2 positive or indeterminate on screening
- Positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment
- Grade 1 or above routine laboratory parameters. Hyperbilirubinaemia to be considered an exclusion criterion only when confirmed to be conjugated bilirubinaemia
- Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.
- Unlikely to comply with protocol
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Group 1 - Combination arm
All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20. At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm. |
8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
|
有源比较器:Group 2 - Non-combination arm
All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28. At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm. |
8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Magnitude of antibody response
大体时间:Four weeks after final immunisation
|
Magnitude (reciprocal mean endpoint titre and concentration) of systemic Immunoglobulin G (IgG) binding antibody responses to CN54rgp140 measured four weeks after the final immunisation.
|
Four weeks after final immunisation
|
Adverse Events
大体时间:Every four weeks up to 32 weeks
|
Grade 3 or above local solicited adverse event Grade 3 or above systemic clinical and laboratory solicited adverse event Any grade of adverse event that results in a clinical decision to discontinue further immunisations
|
Every four weeks up to 32 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Magnitude of neutralising antibody (Nab) responses
大体时间:Four weeks after the final immunisation
|
Confirmation of specific investigations will be provided at a later date.
|
Four weeks after the final immunisation
|
Magnitude of T-cell and B-cell responses
大体时间:Four weeks after the final immunisation
|
Confirmation of specific investigations will be provided at a later date.
|
Four weeks after the final immunisation
|
Magnitude of mucosal IgG and IgA antibody responses
大体时间:Four weeks after the final immunisation
|
Confirmation of specific investigations will be provided at a later date.
|
Four weeks after the final immunisation
|
Magnitude of antibody-dependent cell-mediated cytotoxicity or Antibody-dependent cell-mediated viral inhibition
大体时间:From first immunisation
|
Confirmation of specific investigations will be provided at a later date.
|
From first immunisation
|
Magnitude of systemic Immunoglobulin A (IgA) binding antibody responses
大体时间:Four weeks after the final immunisation
|
Confirmation of specific investigations will be provided at a later date.
|
Four weeks after the final immunisation
|
合作者和调查者
调查人员
- 首席研究员:Sheena McCormack, MSc, FRCP、Senior Clinical Scientist
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
艾滋病病毒的临床试验
-
Hospital Clinic of Barcelona完全的
-
Rajavithi Hospital未知研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的免疫状态 | 研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的 HIV 病毒载量泰国
-
National Institute of Allergy and Infectious Diseases...完全的HIV-1 感染 | HIV抗体 | 中和抗体 | 病毒载量 | 单克隆抗体美国
-
AIDS Healthcare FoundationUniversity of California, Los Angeles完全的
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University of Bergen; Centre... 和其他合作者完全的
-
Hospital Universitari Vall d'Hebron Research InstituteGilead Sciences完全的
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixa完全的
DNA的临床试验
-
Amsterdam UMC, location VUmcDutch Kidney Foundation; B.Braun Avitum AG; Niercentrum aan de Amstel尚未招聘晚期肾脏疾病
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials Network; IPPOX Foundation; CHAVI; MHRP完全的
-
National Institute of Allergy and Infectious Diseases...完全的
-
Universitaire Ziekenhuizen KU Leuven招聘中